E Fund Management Co. Ltd. Takes Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

E Fund Management Co. Ltd. bought a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 12,481 shares of the company’s stock, valued at approximately $217,000.

Other institutional investors also recently bought and sold shares of the company. Finepoint Capital LP raised its holdings in shares of Travere Therapeutics by 0.3% in the third quarter. Finepoint Capital LP now owns 1,782,267 shares of the company’s stock worth $24,934,000 after buying an additional 5,539 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Travere Therapeutics by 3.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company’s stock valued at $24,222,000 after acquiring an additional 64,744 shares during the period. Parkman Healthcare Partners LLC raised its stake in Travere Therapeutics by 12.0% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,086,067 shares of the company’s stock worth $15,194,000 after acquiring an additional 116,175 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its position in Travere Therapeutics by 37.1% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 843,300 shares of the company’s stock worth $11,798,000 after acquiring an additional 228,300 shares during the period. Finally, Jennison Associates LLC purchased a new stake in Travere Therapeutics during the 4th quarter valued at about $14,222,000.

Analyst Ratings Changes

Several research analysts have recently issued reports on TVTX shares. Canaccord Genuity Group raised their price objective on Travere Therapeutics from $22.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Piper Sandler increased their price target on shares of Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, November 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Travere Therapeutics in a research note on Friday, February 21st. Evercore ISI increased their price objective on shares of Travere Therapeutics from $33.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Finally, HC Wainwright raised their target price on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, January 15th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Travere Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $30.62.

Insider Activity

In other news, CEO Eric M. Dube sold 11,375 shares of the business’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $24.04, for a total transaction of $273,455.00. Following the transaction, the chief executive officer now owns 419,173 shares of the company’s stock, valued at approximately $10,076,918.92. The trade was a 2.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Sandra Calvin sold 15,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $17.22, for a total transaction of $258,300.00. Following the completion of the sale, the chief accounting officer now directly owns 54,927 shares of the company’s stock, valued at approximately $945,842.94. This trade represents a 21.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 206,335 shares of company stock worth $4,453,012 over the last three months. Insiders own 3.75% of the company’s stock.

Travere Therapeutics Price Performance

NASDAQ:TVTX opened at $18.09 on Monday. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week high of $25.29. The stock’s 50-day moving average price is $20.24 and its 200-day moving average price is $17.49. The stock has a market capitalization of $1.61 billion, a PE ratio of -4.41 and a beta of 0.75.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.15). Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The company had revenue of $74.79 million for the quarter, compared to analysts’ expectations of $72.38 million. As a group, equities analysts expect that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.